News | June 09, 2024
Gavi outlines plans to support access to new vaccines
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
The demand in Africa for COVID-19 vaccines has declined
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
The institution will be spread over an area of more than 8 acres
India has reached to nearly 6,000 bio-startups from 50 in the past 10 years
Subscribe To Our Newsletter & Stay Updated
